Cargando…

Haemodynamic definitions and updated clinical classification of pulmonary hypertension

Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonneau, Gérald, Montani, David, Celermajer, David S., Denton, Christopher P., Gatzoulis, Michael A., Krowka, Michael, Williams, Paul G., Souza, Rogerio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351336/
https://www.ncbi.nlm.nih.gov/pubmed/30545968
http://dx.doi.org/10.1183/13993003.01913-2018
_version_ 1783390555795881984
author Simonneau, Gérald
Montani, David
Celermajer, David S.
Denton, Christopher P.
Gatzoulis, Michael A.
Krowka, Michael
Williams, Paul G.
Souza, Rogerio
author_facet Simonneau, Gérald
Montani, David
Celermajer, David S.
Denton, Christopher P.
Gatzoulis, Michael A.
Krowka, Michael
Williams, Paul G.
Souza, Rogerio
author_sort Simonneau, Gérald
collection PubMed
description Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.
format Online
Article
Text
id pubmed-6351336
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-63513362019-02-06 Haemodynamic definitions and updated clinical classification of pulmonary hypertension Simonneau, Gérald Montani, David Celermajer, David S. Denton, Christopher P. Gatzoulis, Michael A. Krowka, Michael Williams, Paul G. Souza, Rogerio Eur Respir J Series Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH. European Respiratory Society 2019-01-24 /pmc/articles/PMC6351336/ /pubmed/30545968 http://dx.doi.org/10.1183/13993003.01913-2018 Text en Copyright ©ERS 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Series
Simonneau, Gérald
Montani, David
Celermajer, David S.
Denton, Christopher P.
Gatzoulis, Michael A.
Krowka, Michael
Williams, Paul G.
Souza, Rogerio
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
title Haemodynamic definitions and updated clinical classification of pulmonary hypertension
title_full Haemodynamic definitions and updated clinical classification of pulmonary hypertension
title_fullStr Haemodynamic definitions and updated clinical classification of pulmonary hypertension
title_full_unstemmed Haemodynamic definitions and updated clinical classification of pulmonary hypertension
title_short Haemodynamic definitions and updated clinical classification of pulmonary hypertension
title_sort haemodynamic definitions and updated clinical classification of pulmonary hypertension
topic Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351336/
https://www.ncbi.nlm.nih.gov/pubmed/30545968
http://dx.doi.org/10.1183/13993003.01913-2018
work_keys_str_mv AT simonneaugerald haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension
AT montanidavid haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension
AT celermajerdavids haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension
AT dentonchristopherp haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension
AT gatzoulismichaela haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension
AT krowkamichael haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension
AT williamspaulg haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension
AT souzarogerio haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension